Biotechnology Letters

, Volume 30, Issue 3, pp 475–479 | Cite as

Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses

  • Jayanta Haldar
  • Jianzhu Chen
  • Terrence M. Tumpey
  • Larisa V. Gubareva
  • Alexander M. Klibanov
Original Research Paper


Glass slides painted with the hydrophobic long-chained polycation N,N-dodecyl,methyl-polyethylenimine (N,N-dodecyl,methyl-PEI) are highly lethal to waterborne influenza A viruses, including not only wild-type human and avian strains but also their neuraminidase mutants resistant to currently used anti-influenza drugs.


Antiviral Polyethylenimine Quaternary amines Relenza Tamiflu 



This work was partly supported by the US Army through the Institute of Solider Nanotechnology under contact DAAD-19-02-D0002 with the Army Research Office and by NIH grant AI56267. We wish to thank Dr. Alexander Klimov (Influenza Division, CDC) for providing wild-type and oseltamivir-resistant strains of influenza A/Wuhan/359/95 (H3N2)-like virus.


  1. Dowdle WR (2006) Influenza pandemic periodicity, virus recycling, and the art of risk assessment. Emerg Infect Dis 12:34–39PubMedGoogle Scholar
  2. Gubareva LV, Bethell R, Hart GJ, Murti KG, Penn CR, Webster RG (1996) Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-Guanidino-Neu5Ac2en. J Virol 70:1818–1827PubMedGoogle Scholar
  3. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257–1262PubMedCrossRefGoogle Scholar
  4. Gubareva LV, Kaiser L, Hayden FG (2000) Influenza virus neuraminidase inhibitors. Lancet 355:827–835PubMedCrossRefGoogle Scholar
  5. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG (2001) Selection of influenza virus mutations in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523–531PubMedCrossRefGoogle Scholar
  6. Gubareva LV, Webster RG, Hayden FG (2002) Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res 53:47–61PubMedCrossRefGoogle Scholar
  7. Haldar J, An D, Álvarez de Cienfuegos L, Chen J, Klibanov AM (2006) Polymeric coatings that inactivate both influenza virus and pathogenic bacteria. Proc Natl Acad Sci USA 103:17667–17671PubMedCrossRefGoogle Scholar
  8. Haldar J, Weight AK, Klibanov AM (2007) Preparation, application, and testing of permanently antibacterial and antiviral coatings. Nat Protoc 2 (in press)Google Scholar
  9. Herlocher ML, Truscon R, Elias S, Yen H-L, Roberts NA, Ohmit SE, Monto AS (2004) Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 190:1627–1630PubMedCrossRefGoogle Scholar
  10. Hiti AL, Nayak DP (1982) Complete nucleotide sequence of the neuraminidase gene of human influenza virus A/WSN/33. J Virol 41:730–734PubMedGoogle Scholar
  11. Jackson HC, Roberts N, Wang MZ, Belshe R (2000) Management of influenza; use of new antivirals and resistance perspective. Clin Drug Investig 20:447–454CrossRefGoogle Scholar
  12. Kawaoka Y, Krauss S, Webster RG (1989) Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 63:4603–4608PubMedGoogle Scholar
  13. Klibanov AM (2007) Permanently microbicidal materials coatings. J Mater Chem 17:2479–2482CrossRefGoogle Scholar
  14. Lewis K, Klibanov AM (2005) Surpassing nature: rational design of sterile-surface materials. Trends Biotechnol 23:343–348PubMedCrossRefGoogle Scholar
  15. Mishin VP, Hayden FG, Gubareva LV (2005) Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515–4520PubMedCrossRefGoogle Scholar
  16. Moscona A (2005) Neuraminidase inhibitors for influenza. N Engl J Med 353:1363–1373PubMedCrossRefGoogle Scholar
  17. Park D, Wang J, Klibanov AM (2006) One-step, painting-like coating procedures to make surfaces highly and permanently bactericidal. Biotechnol Prog 22:584–589PubMedCrossRefGoogle Scholar
  18. Roberts NA (2001) Treatment of influenza with neuraminidase inhibitors: virological implication. Philos Trans R Soc Lond B 356:1895–1897CrossRefGoogle Scholar
  19. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, Fanning TG (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437:889–893PubMedCrossRefGoogle Scholar
  20. Van Rompuy L, Jou WM, Huylebroeck D, Friers W (1982) Complete nucleotide sequence of a human influenza neuraminidase gene of subtype N2 (A/Victoria/3/75). J Mol Biol 161:1–11PubMedCrossRefGoogle Scholar
  21. Webster RG, Peiris M, Chen H, Guan Y (2006) H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 12:3–8PubMedGoogle Scholar
  22. Wright PF, Webster RG (2001) Orthomyxoviruses, fields virology. Lippincott Williams & Wilkins, Philadelphia, pp 1533–1579Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2007

Authors and Affiliations

  • Jayanta Haldar
    • 1
  • Jianzhu Chen
    • 2
  • Terrence M. Tumpey
    • 3
  • Larisa V. Gubareva
    • 3
  • Alexander M. Klibanov
    • 1
  1. 1.Departments of Chemistry and Biological EngineeringMassachusetts Institute of TechnologyCambridgeUSA
  2. 2.Center for Cancer Research and Department of BiologyMassachusetts Institute of TechnologyCambridgeUSA
  3. 3.Centers for Disease Control and PreventionAtlantaUSA

Personalised recommendations